Position in ZYME
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,374,270
+$489,898 QoQ
Shares Held
54,883
+63.4% QoQ
Ownership
0.075%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Campbell & CO Investment Adviser LLC holds $45,287,811 across 43 Biotechnology names. ZYME ranks #9 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
9,034 | $6,597,078 | |
| 2 | KRYS |
Krystal Biotech, Inc.
|
17,795 | $4,596,804 | |
| 3 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
83,617 | $3,036,969 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
29,130 | $2,832,892 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,580 | $2,491,693 | |
| 6 | TECH |
BIO-TECHNE Corp
|
41,339 | $2,160,376 | |
| 7 | RPRX |
Royalty Pharma plc
|
31,202 | $1,496,759 | |
| 8 | PRTA |
Prothena Corp Public Ltd Co
|
142,587 | $1,385,945 |
All Filings in ZYME
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,374,270 | 54,883 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $884,372 | 33,588 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $554,980 | 32,493 | Shares | Sole | 2025-10-28 | |
| 2025-06-30 | $188,061 | 14,985 | Shares | Sole | 2025-08-07 | |
| 2024-06-30 | $258,389 | 30,363 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||